What is Generate Biomedicines, Inc. 's short-term investments?

Generate Biomedicines, Inc. (GENB) reported short-term investments of $356.07M in Q1 2026.

What does short-term investments mean?

Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.

Generate Biomedicines, Inc. GENB Short-Term Investments

Short-Term Investments at other companies

SSR MiningSSRM

$40.27M+85.8%

RepligenRGEN

$201.88M—

Chime Financial, Inc. Class A Common StockCHYM

$403.61M—

Alignment HealthcareALHC

$20.71M-37.9%

Ligand PharmaceuticalsLGND

$664.33M+313%

GenpactG

$350M—

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's short-term investments?: Generate Biomedicines, Inc. (GENB) reported short-term investments of $356.07M in Q1 2026.
What does short-term investments mean?: Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.